Details
Stereochemistry | RACEMIC |
Molecular Formula | C11H12I3NO2 |
Molecular Weight | 570.9319 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(CC1=C(I)C(N)=C(I)C=C1I)C(O)=O
InChI
InChIKey=OIRFJRBSRORBCM-UHFFFAOYSA-N
InChI=1S/C11H12I3NO2/c1-2-5(11(16)17)3-6-7(12)4-8(13)10(15)9(6)14/h4-5H,2-3,15H2,1H3,(H,16,17)
Originator
Sources: http://www.springer.com/kr/book/9783642695179
Curator's Comment: M. Sovak. Radiocontrast Agents. (1984), p. 383. ISBN13: 9783642695179
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
75 g single, oral Overdose |
unknown, 42 years n = 1 Health Status: unknown Condition: used for diagnosis Age Group: 42 years Sex: M Population Size: 1 Sources: |
Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (1 patient) Sources: |
3 g single, oral Recommended |
unknown, adult n = 48 Health Status: unknown Condition: used for diagnosis Age Group: adult Sex: unknown Population Size: 48 Sources: |
Other AEs: Gastrointestinal disorders... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Diarrhea | 1 patient Disc. AE |
75 g single, oral Overdose |
unknown, 42 years n = 1 Health Status: unknown Condition: used for diagnosis Age Group: 42 years Sex: M Population Size: 1 Sources: |
Gastrointestinal disorders | 39 patients | 3 g single, oral Recommended |
unknown, adult n = 48 Health Status: unknown Condition: used for diagnosis Age Group: adult Sex: unknown Population Size: 48 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
The activity of antioxidant enzymes and the content of uncoupling protein-1 in the brown adipose tissue of hypothyroid rats: comparison with effects of iopanoic acid. | 2001 |
|
A test of the hypothesis that T3 is the "seasonality" thyroid hormone in American tree sparrows (Spizella arborea): intracerebroventricular infusion of iopanoic acid, an inhibitor of T3 synthesis and degradation. | 2001 Mar |
|
Recombinant lysine:N(6)-hydroxylase: effect of cysteine-->alanine replacements on structural integrity and catalytic competence. | 2002 Feb 11 |
|
Effect of iodine or iopanoic acid on thyroid Ca2+/NADPH-dependent H2O2-generating activity and thyroperoxidase in toxic diffuse goiters. | 2002 Sep |
|
Thyroid status, but not insulin status, affects expression of avian uncoupling protein mRNA in chicken. | 2003 Apr |
|
Acute decrease in circulating T3 levels enhances, but does not normalise, the GH response to GHRP-6 plus GHRH in thyrotoxicosis. | 2003 Aug |
|
Is there a place for thyroidectomy in older patients with thyrotoxic storm and cardiorespiratory failure? | 2003 Oct |
|
Inhibition of drug binding to human serum albumin by cholecystographic agents. | 2003 Sep |
|
Thyroid hormones interact with glucocorticoids to affect somatotroph abundance in chicken embryonic pituitary cells in vitro. | 2003 Sep |
|
Treatment of hyperthyroidism associated with thyrotropin-secreting pituitary adenomas with iopanoic acid. | 2004 Feb |
|
Iopanoic acid in the management of neonatal Graves' disease. | 2004 Feb |
|
Expression of type II iodothyronine deiodinase marks the time that a tissue responds to thyroid hormone-induced metamorphosis in Xenopus laevis. | 2004 Feb 1 |
|
Oral contrast-enhanced CT cholangiography--an initial experience. | 2004 Jan |
|
Electrospray ionization mass spectrometry as a tool for determination of drug binding sites to human serum albumin by noncovalent interaction. | 2005 |
|
Effect of iopanoic acid on radioiodine therapy of hyperthyroidism: long-term outcome of a randomized controlled trial. | 2005 Dec |
|
Thin-section multiplanar reformats from multidetector-row CT data: utility for assessment of regional tumor extent in non-small cell lung cancer. | 2005 Oct |
|
Comparison of enhancing effects of different goitrogen treatments in combination with beta-estradiol-3-benzoate for establishing a rat two-stage thyroid carcinogenesis model to detect modifying effects of estrogenic compounds. | 2006 Jan |
|
Morphological and biochemical changes in the Harderian gland of hypothyroid rats. | 2008 Feb |
|
Structural basis of GC-1 selectivity for thyroid hormone receptor isoforms. | 2008 Jan 31 |
|
Effects of different treatments for hyperthyroidism on the hypothalamic-pituitary-adrenal axis. | 2008 Sep |
|
Implication of type 3 deiodinase induction in zebrafish fin regeneration. | 2010 Aug 1 |
|
Analysis by LC/ESI-MS of iophenoxic acid derivatives and evaluation as markers of oral baits to deliver pharmaceuticals to wildlife. | 2010 Jul 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1304283
Take 500 mg orally twice a day for the first 3 weeks.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QV08AC06
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
||
|
WHO-ATC |
V08AC06
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
||
|
NCI_THESAURUS |
C28500
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | |||
|
41706
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | |||
|
5967
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | |||
|
3735
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | |||
|
3345
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | |||
|
FE9794P71J
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | |||
|
IOPANOIC ACID
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | Description: A light yellowish white powder; odour, faint, characteristic. Solubility: Practically insoluble in water; soluble in ethanol (~750 g/l) TS, and acetone R; dissolves in solutions of alkali hydroxides. Category: Radiocontrast medium. Storage: Iopanoic acid should be kept in a tightly closed container, protected from light. Iopanoic acid is gradually affected by light. Requirements: Iopanoic acid contains not less than 97.0% and not more than the equivalent of 101.0% of C11H12I3NO2, calculated with reference to the dried substance. | ||
|
SUB08240MIG
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | |||
|
637485
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
ALTERNATIVE | |||
|
202-539-9
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | |||
|
DB08946
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | |||
|
M6371
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | Merck Index | ||
|
17879-93-5
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
SUPERSEDED | |||
|
Iopanoic acid
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | |||
|
96-83-3
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | |||
|
DTXSID6023159
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | |||
|
CHEMBL867
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | |||
|
C65942
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | |||
|
1465
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY | |||
|
D007480
Created by
admin on Sun Dec 18 19:03:20 UTC 2022 , Edited by admin on Sun Dec 18 19:03:20 UTC 2022
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)